Literature DB >> 25652980

Reproducibility: Standardize antibodies used in research.

Andrew Bradbury1, Andreas Plückthun2.   

Abstract

Mesh：

Substances：

Year:  2015        PMID： 25652980     DOI： 10.1038/518027a

Source DB:  PubMed          Journal:  Nature        ISSN： 0028-0836            Impact factor:   49.962


× No keyword cloud information.
  10 in total

1.  Continuous cultures of fused cells secreting antibody of predefined specificity.

Authors:  G Köhler; C Milstein
Journal:  Nature       Date:  1975-08-07       Impact factor: 49.962

2.  Drug development: Raise standards for preclinical cancer research.

Authors:  C Glenn Begley; Lee M Ellis
Journal:  Nature       Date:  2012-03-28       Impact factor: 49.962

3.  Multiplexed immuno-precipitation with 1725 commercially available antibodies to cellular proteins.

Authors:  Heidi Slaastad; Weiwei Wu; Luiz Goullart; Veronika Kanderova; Geir Tjønnfjord; Jan Stuchly; Tomas Kalina; Anders Holm; Fridtjof Lund-Johansen
Journal:  Proteomics       Date:  2011-11-07       Impact factor: 3.984

Review 4.  Engineering novel binding proteins from nonimmunoglobulin domains.

Authors:  H Kaspar Binz; Patrick Amstutz; Andreas Plückthun
Journal:  Nat Biotechnol       Date:  2005-10       Impact factor: 54.908

Review 5.  Antibody validation.

Authors:  Jennifer Bordeaux; Allison Welsh; Seema Agarwal; Elizabeth Killiam; Maria Baquero; Jason Hanna; Valsamo Anagnostou; David Rimm
Journal:  Biotechniques       Date:  2010-03       Impact factor: 1.993

Review 6.  Aptamers and the RNA world, past and present.

Authors:  Larry Gold; Nebojsa Janjic; Thale Jarvis; Dan Schneider; Jeffrey J Walker; Sheri K Wilcox; Dom Zichi
Journal:  Cold Spring Harb Perspect Biol       Date:  2012-03-01       Impact factor: 10.005

Review 7.  A genecentric Human Protein Atlas for expression profiles based on antibodies.

Authors:  Lisa Berglund; Erik Björling; Per Oksvold; Linn Fagerberg; Anna Asplund; Cristina Al-Khalili Szigyarto; Anja Persson; Jenny Ottosson; Henrik Wernérus; Peter Nilsson; Emma Lundberg; Asa Sivertsson; Sanjay Navani; Kenneth Wester; Caroline Kampf; Sophia Hober; Fredrik Pontén; Mathias Uhlén
Journal:  Mol Cell Proteomics       Date:  2008-10       Impact factor: 5.911

8.  Policy: NIH plans to enhance reproducibility.

Authors:  Francis S Collins; Lawrence A Tabak
Journal:  Nature       Date:  2014-01-30       Impact factor: 49.962

9.  Commercial antibodies and their validation.

Authors:  Jla Voskuil
Journal:  F1000Res       Date:  2014-10-02

10.  On the reproducibility of science: unique identification of research resources in the biomedical literature.

Authors:  Nicole A Vasilevsky; Matthew H Brush; Holly Paddock; Laura Ponting; Shreejoy J Tripathy; Gregory M Larocca; Melissa A Haendel
Journal:  PeerJ       Date:  2013-09-05       Impact factor: 2.984
  10 in total
  207 in total

1.  Reply to Dimitrov et al.: VelociSuite technologies are a foundation for rapid therapeutic antibody development.

Authors:  Christos A Kyratsous; William Olson; Neil Stahl
Journal:  Proc Natl Acad Sci U S A       Date:  2015-08-28       Impact factor: 11.205

2.  A switchable yeast display/secretion system.

Authors:  James A Van Deventer; Ryan L Kelly; Saravanan Rajan; K Dane Wittrup; Sachdev S Sidhu
Journal:  Protein Eng Des Sel       Date:  2015-09-01       Impact factor: 1.650

3.  Antibody anarchy: A call to order.

Authors:  Monya Baker
Journal:  Nature       Date:  2015-11-26       Impact factor: 49.962

4.  Research antibodies: do not use them to stain your reputation.

Authors:  Eric Delpire
Journal:  Am J Physiol Cell Physiol       Date:  2015-12-01       Impact factor: 4.249

Review 5.  The apelinergic system: a perspective on challenges and opportunities in cardiovascular and metabolic disorders.

Authors:  Eric Marsault; Catherine Llorens-Cortes; Xavier Iturrioz; Hyung J Chun; Olivier Lesur; Gavin Y Oudit; Mannix Auger-Messier
Journal:  Ann N Y Acad Sci       Date:  2019-06-25       Impact factor: 5.691

Review 6.  Precision diagnostics: moving towards protein biomarker signatures of clinical utility in cancer.

Authors:  Carl A K Borrebaeck
Journal:  Nat Rev Cancer       Date:  2017-02-03       Impact factor: 60.716

7.  Validation of Isoform- and Mutation-Specific RAS Antibodies.

Authors:  Andrew M Waters; Channing J Der
Journal:  Methods Mol Biol       Date:  2021

8.  Evaluation of the selectivity and sensitivity of isoform- and mutation-specific RAS antibodies.

Authors:  Andrew M Waters; Irem Ozkan-Dagliyan; Angelina V Vaseva; Nicole Fer; Leslie A Strathern; G Aaron Hobbs; Basile Tessier-Cloutier; William K Gillette; Rachel Bagni; Gordon R Whiteley; James L Hartley; Frank McCormick; Adrienne D Cox; Peter J Houghton; David G Huntsman; Mark R Philips; Channing J Der
Journal:  Sci Signal       Date:  2017-09-26       Impact factor: 8.192

9.  Epitope mapping of commercial antibodies that detect myocilin.

Authors:  Athéna C Patterson-Orazem; Shannon E Hill; Michael P Fautsch; Raquel L Lieberman
Journal:  Exp Eye Res       Date:  2018-05-09       Impact factor: 3.467

10.  Systematic Activity Maturation of a Single-Domain Antibody with Non-canonical Amino Acids through Chemical Mutagenesis.

Authors:  Philip R Lindstedt; Francesco A Aprile; Pietro Sormanni; Robertinah Rakoto; Christopher M Dobson; Gonçalo J L Bernardes; Michele Vendruscolo
Journal:  Cell Chem Biol       Date:  2020-11-19       Impact factor: 8.116
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.